Recent News

• 06.11.2025 - Annual Meeting
• 06.11.2025 - Annual Meeting
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 05.29.2025 - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
• 05.29.2025 - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
• 05.29.2025 - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
• 05.19.2025 - CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
• 05.19.2025 - CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
• 05.19.2025 - CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

Recent Filings

• 05.28.2025 - 8-K Current report
• 05.20.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.20.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.20.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - 8-K Current report